Treatment ofHelicobacter pyloriinfection: Meeting the challenge of antimicrobial resistance

Association of a probiotic to a Helicobacter pylorieradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study

(2013) Tomás Navarro-Rodriguez et al.   BMC GASTROENTEROLOGY

Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study

(2013) Xiao Liang et al.   Clinical Gastroenterology and Hepatology

Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment ofHelicobacter pyloriInfection

(2013) Marino Venerito et al.   DIGESTION

Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection

(2013) J. P. Gisbert et al.   DIGESTIVE DISEASES AND SCIENCES

Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance

(2013) Javier Molina–Infante et al.   GASTROENTEROLOGY

Randomised clinical trial comparing sequential and concomitant therapies forHelicobacter pylorieradication in routine clinical practice

(2013) Adrian G McNicholl et al.   GUT

The Effects of Multistrain Probiotic Compound on Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection: A Randomized Placebo-Controlled Triple-Blind Study

(2013) Ahmad Shavakhi et al.   HELICOBACTER

Ten-Day Quadruple Therapy Comprising Proton-Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate forHelicobacter pyloriInfection after Failure of Sequential Therapy

(2013) Ping-I Hsu et al.   HELICOBACTER

Clinical Outcomes of Two-Week Sequential and Concomitant Therapies forHelicobacter pyloriEradication: A Randomized Pilot Study

(2013) Ji Hyun Lim et al.   HELICOBACTER

Clinical Evaluation of a Ten-Day Regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the Eradication ofHelicobacter pyloriin a High Clarithromycin Resistance Area

(2013) Sotirios D. Georgopoulos et al.   HELICOBACTER

Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication

(2013) Qing Guo et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre

(2013) A. O’Connor et al.   IRISH JOURNAL OF MEDICAL SCIENCE

Treatment for H. pylori Infection

(2013) Nimish Vakil et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Efficacy of Helicobacter pylori Eradication Therapy on Functional Dyspepsia

(2013) Bing Zhao et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Meta-analysis: Is sequential therapy superior to standard triple therapy forHelicobacter pyloriinfection in Asian adults?

(2013) Hyuk Yoon et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Eradication of Helicobacter pylori According to 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance

(2013) H. J. Lee et al.   JOURNAL OF INFECTIOUS DISEASES

Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicateH. pyloriinfection

(2013) Javier P. Gisbert et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Eradication of gastric cancer is now both possible and practical

(2013) Akiko Shiotani et al.   SEMINARS IN CANCER BIOLOGY

Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study

(2013) Angelo Zullo et al.   Clinics and Research in Hepatology and Gastroenterology

Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients

(2013) Abdoulaye Seck et al.   Annals of Clinical Microbiology and Antimicrobials

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

(2013) L. Gatta et al.   BMJ-British Medical Journal

Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures

(2012) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Modified sequential therapy regimens for Helicobacter pylori eradication: A systematic review

(2012) Angelo Zullo et al.   DIGESTIVE AND LIVER DISEASE

Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection

(2012) Alessandro Federico et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption

(2012) Francis Megraud et al.   GUT

Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics + Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy

(2012) Marco Manfredi et al.   HELICOBACTER

Helicobacter pylori Infection: Sequential Therapy Followed by Levofloxacin-Containing Triple Therapy provides a Good Cumulative Eradication Rate

(2012) Marco Manfredi et al.   HELICOBACTER

Evaluation of a Four-drug, Three-antibiotic, Nonbismuth-containing “Concomitant” Therapy as First-line Helicobacter pylori Eradication Regimen in Greece

(2012) Sotirios Georgopoulos et al.   HELICOBACTER

Extragastric Manifestations of Helicobacter pylori Infection

(2012) Marko Banić et al.   HELICOBACTER

Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains

(2012) Javier Molina-Infante et al.   HELICOBACTER

Comparison of Hybrid and Sequential Therapies forHelicobacter pyloriEradication in Iran: A Prospective Randomized Trial

(2012) Hossein Sardarian et al.   HELICOBACTER

Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial

(2012) C.-H. Kuo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection

(2012) Javier P. Gisbert et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Comparative Study of Helicobacter pylori Eradication Rates With 5-day Quadruple “Concomitant” Therapy and 7-day Standard Triple Therapy

(2012) Seung Young Kim et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Meta-Analysis of the Efficacy and Safety of Lactobacillus-containing and Bifidobacterium-containing Probiotic Compound Preparation in Helicobacter pylori Eradication Therapy

(2012) Zhen-Hua Wang et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Nonbismuth Quadruple “Concomitant” Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication

(2012) Sotirios Georgopoulos et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2012) Jyh-Ming Liou et al.   LANCET

Helicobacter pylorieradication: Sequential therapy andLactobacillus reuterisupplementation

(2012) Cesare Efrati   WORLD JOURNAL OF GASTROENTEROLOGY

Adjuvant probiotics improve the eradication effect of triple therapy forHelicobacter pyloriinfection

(2012) Yi-Qi Du   WORLD JOURNAL OF GASTROENTEROLOGY

Levofloxacin/amoxicillin-based schemesvsquadruple therapy forHelicobacter pylorieradication in second-line

(2012) Simona Di Caro   WORLD JOURNAL OF GASTROENTEROLOGY

Rescue Therapy forHelicobacter pyloriInfection 2012

(2012) Javier P. Gisbert   Gastroenterology Research and Practice

Impact ofLactobacillus reuteriSupplementation on Anti-Helicobacter pyloriLevofloxacin-Based Second-Line Therapy

(2012) Veronica Ojetti et al.   Gastroenterology Research and Practice

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection

(2011) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Treating Bugs with Bugs: The Role of Probiotics as Adjunctive Therapy for Helicobacter pylori

(2011) Sheila M Wilhelm et al.   ANNALS OF PHARMACOTHERAPY

DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin

(2011) Philippe Lehours et al.   BMC GASTROENTEROLOGY

Gastric Wash-Based Molecular Testing for Antibiotic Resistance in Helicobacter pylori

(2011) Satoshi Baba et al.   DIGESTION

Moxifloxacin-Containing Triple Therapy versus Bismuth-Containing Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis

(2011) Cheng Wu et al.   HELICOBACTER

Effectiveness and Safety of Repeated Quadruple Therapy in Helicobacter pylori Infection After Failure of Second-line Quadruple Therapy

(2011) Sang Kyu Lee et al.   HELICOBACTER

Is There a Benefit to Extending the Duration of Helicobacter pylori Sequential Therapy to 14 Days?

(2011) Ping I. Hsu et al.   HELICOBACTER

Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days

(2011) Ping-I. Hsu et al.   HELICOBACTER

Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days

(2011) Yuan LI et al.   Journal of Digestive Diseases

Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study

(2011) L. Boyanova et al.   JOURNAL OF MEDICAL MICROBIOLOGY

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

(2011) E Robert Greenberg et al.   LANCET

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET

Optimal therapy for Helicobacter pylori infections

(2011) Emiko Rimbara et al.   Nature Reviews Gastroenterology & Hepatology

Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment

(2010) H. Szajewska et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults

(2010) Xiaolin Pan et al.   CLINICAL THERAPEUTICS

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

(2010) M. Romano et al.   GUT

The Evolution of Helicobacter pylori Antibiotics Resistance Over 10 Years in Beijing, China

(2010) Wen Gao et al.   HELICOBACTER

Sequential Therapy for Helicobacter pylori Eradication

(2010) Javier P. Gisbert et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects

(2010) V. W. Y. Lee et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance

(2010) Qing ZHENG et al.   Journal of Digestive Diseases

Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori

(2010) Kenro Hirata et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Distribution ofgyrAmutations in fluoroquinolone-resistantHelicobacter pyloristrains

(2010) Li-Hui Wang   WORLD JOURNAL OF GASTROENTEROLOGY

Should quinolones come first in Helicobacter pylori therapy?

(2010) Marco Berning et al.   Therapeutic Advances in Gastroenterology

Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability

(2009) Jay Luther et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Sequential Therapy or Triple Therapy for Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults and Children

(2009) Luigi Gatta et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation

(2009) H. Suzuki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations

(2009) K. Murakami et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori Infection

(2009) Deng–Chyang Wu et al.   Clinical Gastroenterology and Hepatology

Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori

(2009) Vincenzo De Francesco et al.   DIGESTIVE AND LIVER DISEASE

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy ofHelicobacter pyloriinfection

(2009) Jyh-Chin Yang et al.   Expert Opinion on Drug Metabolism & Toxicology

Geographic map and evolution of primaryHelicobacter pyloriresistance to antibacterial agents

(2009) Lyudmila Boyanova et al.   Expert Review of Anti-Infective Therapy

Meta-Analysis: Lactobacillus Containing Quadruple Therapy Versus Standard Triple First-Line Therapy for Helicobacter pylori Eradication

(2009) Jian Zou et al.   HELICOBACTER

Annual Change of Primary Resistance to Clarithromycin among Helicobacter pylori Isolates from 1996 through 2008 in Japan

(2009) Noriyuki Horiki et al.   HELICOBACTER

Meta-analysis: Four-Drug, Three-Antibiotic, Non-bismuth-Containing “Concomitant Therapy” Versus Triple Therapy forHelicobacter pyloriEradication

(2009) Abdallah Said Essa et al.   HELICOBACTER

Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

(2009) V. De Francesco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of a New Test, GenoType HelicoDR, for Molecular Detection of Antibiotic Resistance in Helicobacter pylori

(2009) E. Cambau et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Second Asia-Pacific Consensus Guidelines forHelicobacter pyloriinfection

(2009) K Ming Fock et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Peptic ulcer disease

(2009) Peter Malfertheiner et al.   LANCET

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication

(2008) S. Di Caro et al.   DIGESTIVE AND LIVER DISEASE

Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy forHelicobacter pyloriEradication: A Meta-Analysis

(2008) Fujun Zhao et al.   HELICOBACTER

Sequential therapy vs. standard triple therapies forHelicobacter pyloriinfection: a meta-analysis

(2008) J. L. Tong et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities

(2008) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY